GSK has submitted US and EU regulatory applications seeking approval of a quadrivalent influenza vaccine for the "active immunisation of adults and children from 3 years of age for the prevention of influenza disease caused by influenza virus types A and B contained in the vaccine."

Eli Lilly and Company (NYSE:LLY) announced the launch of its global Innovation Starts Here initiative which supports Lilly's commitment to speeding the delivery of innovative new medicines to patients around the world.

GlaxoSmithKline (GSK) announced that it has signed an agreement with Daiichi Sankyo Co., Ltd. to form a Joint Venture (JV) which is expected to create the number one vaccines company in Japan.

AstraZeneca announced that MedImmune, its biologics arm, has received approval from the US Food and Drug Administration (FDA) for FluMist® Quadrivalent (Influenza Vaccine Live, Intranasal) in the prevention of influenza. This marks the first four-strain influenza vaccine approved by the FDA.

Bristol-Myers Squibb Company (NYSE:BMY) and Duke Translational Medicine Institute (DTMI) announced the formation of a strategic relationship to broaden interactions between the two organizations. The relationship builds on a decade of collaboration in cardiology, endocrinology, and oncology,

Sanofi and Astellas Pharma Inc. announced that the two companies agreed to dissolve sanofi-aventis Yamanouchi Pharmaceutical Inc., a joint company of Sanofi and Astellas.

Pfizer Inc. (NYSE:PFE) announced the acquisition of privately-held Alacer Corp., the maker and distributor of Emergen-C products, the largest selling branded Vitamin C line in the United States.